In terms of patient cancers in which GSK3-mediated Mcl-1 degradation is inactive, it remains to be determined whether the presence of ERK activation/Thr 163 phosphorylation contributes to resistance upon prolonged drug exposure. Here, MCL1 is linked to cancer.